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ABSTRACT
Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) exhibit potency for the
regeneration of infarcted hearts. Vascular endothelial growth factor (VEGF) is capable of inducing
angiogenesis and can boost stem cell-based therapeutic effects. However, high levels of VEGF can
cause abnormal blood vessel growth and hemangiomas. Thus, a controllable system to induce
therapeutic levels of VEGF is required for cell therapy. We generated an inducible VEGF-secreting
stem cell (VEGF/hUCB-MSC) that controls the expression of VEGF and tested the therapeutic efﬁ-
cacy in rat myocardial infarction (MI) model to apply functional stem cells to MI. To introduce the
inducible VEGF gene cassette into a safe harbor site of the hUCB-MSC chromosome, the transcrip-
tion activator-like effector nucleases system was used. After conﬁrming the integration of the cas-
sette into the locus, VEGF secretion in physiological concentration from VEGF/hUCB-MSCs after
doxycycline (Dox) induction was proved in conditioned media. VEGF secretion was detected in
mice implanted with VEGF/hUCB-MSCs grown via a cell sheet system. Vessel formation was
induced in mice transplanted with Matrigel containing VEGF/hUCB-MSCs treated with Dox. More-
over, seeding of the VEGF/hUCB-MSCs onto the cardiac patch signiﬁcantly improved the left ventri-
cle ejection fraction and fractional shortening in a rat MI model upon VEGF induction. Induced
VEGF/hUCB-MSC patches signiﬁcantly decreased the MI size and ﬁbrosis and increased muscle
thickness, suggesting improved survival of cardiomyocytes and protection from MI damage. These
results suggest that our inducible VEGF-secreting stem cell system is an effective therapeutic
approach for the treatment of MI. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1040–1051
SIGNIFICANCE STATEMENT
Human umbilical cord-derived mesenchymal stem cells harboring an angiogenesis gene, vascular
endothelial growth factor (VEGF), in a safe harbor were generated. This gene cassette was spe-
cifically designed in a drug inducible manner. The engineered stem cells were able to produce
the growth factor at a physiologically relevant concentration. Transplantation of the stem cells
harboring the gene in a rat myocardial infarction model showed greatly improved protection
from heart damage and amelioration of the tissue damage in the infarcted hearts. This study
indicates that inducible VEGF-secreting stem cells represent a potent therapeutic approach for
the treatment of myocardial infarction.
INTRODUCTION
Myocardial infarction (MI) is a serious health and
economic problem and a primary cause of mortal-
ity in developed countries. A primary therapy for
this disease is cardiac regeneration, which repre-
sents a difﬁcult and immense challenge [1, 2].
During the process of MI, the coronary artery is
occluded after plaque rupture. After a few weeks,
the ischemic region is replaced with a thin ﬁbrotic
area that ﬁnally causes cardiac dysfunction [3].
The cardiomyocytes in the ischemic site have a
limited capacity for self-regeneration, and their
repopulation is almost impossible [4]. Thus, other
sources of cells and factors are required to regen-
erate the infarcted region of the heart.
Recently, stem cell-based therapy including
human umbilical cord blood-derived mesenchymal
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stem cells (hUCB-MSCs) has attracted interest for heart regenera-
tion and restored the injured myocardium in certain degrees. Vari-
ous strategies including biomaterials [5], inducing vasculogenesis
[6], and tissue engineering [7] have been applied and the therapy
showed positive effects, restoration of damaged cardiomyocytes,
enhancement of cardiac function and a reduced infarct size to cer-
tain degrees, in preclinical trials [5, 8, 9]. However, stem cell ther-
apy has encountered various problems, such as low survival and
proliferation rates of implanted cells and the reason of these limi-
tations is an insufﬁcient supply of oxygen and nutrient and the
hostile microenvironment of infarcted region. Therefore, to acquire
efﬁcient and rapid therapeutic efﬁcacy of stem cells, providing an
intrinsic vascularization stimulus by growth factors is demanded.
Vascular endothelial growth factor (VEGF) is an important
angiogenic factor that promotes the survival of endothelial cells
(EC) and prevents EC apoptosis [10]. VEGF can be used as a thera-
peutic reagent in ischemic injuries. Rat mesenchymal stem cells
expressing VEGF transiently by adenovirus induced angiogenesis
and protected the remaining cardiomyocytes in MI animal models
[11]. VEGF protein with hepatocyte growth factor (HGF) has also
been demonstrated to have a cardioprotective effect by increasing
the tolerance of cardiomyocytes to ischemia and reducing cardio-
myocyte apoptosis [12]. However, transient gene expression and
protein injection are limited for long-term therapeutic effect
accomplishment in MI. Thus, for long-term gene expression,
retrovirus-mediated gene delivery has been attempted. However,
gene delivery through a retroviral vector for cell transduction also
carries a risk of stem cell neoplastic transformation and oncogene
activation by the long term repeat (LTR) promoter [13]. Therefore,
this long-term expression system has a limit for therapeutic appli-
cation and may cause tumors and insertional mutagenesis via the
incorporation of the growth factor gene into a critical region of
the host chromosome. Moreover, high and uncontrollable level of
VEGF itself also has the potential to cause abnormal blood vessel
formation and hemangiomas [14].
One way to overcome these issues is to use a controllable sys-
tem for the transgene and to ensure integration into a safe harbor
site in the chromosome. The tetracycline(Tet)-controlled system is
commonly used for gene regulation in mammalian cells [15]. In
this system, rtTA binds to the Tet-On promoter in the presence of
doxycycline (Dox) and activates Tet-On/CMV-driven gene tran-
scription [16]. For safe gene insertion into a safe harbor site of
human chromosome, genome editing technologies have been
used; zinc-ﬁnger nucleases, transcription activator-like effector
nucleases (TALENs), and recent clustered regulatory interspaced
short palindromic repeat (CRISPR)/Cas9 [17]. TALENs are target-
able nucleases composed of a FokI nuclease domain and custom-
izable DNA binding domain [18]. The DNA-binding domain has
conserved repeats that originate from transcription activator-like
effectors found in Xanthomonas plant pathogens. TALENs have
rapidly emerged as a genome editing technology with high efﬁ-
ciency and low toxicity that allow safe, targeted nonviral gene
delivery to a speciﬁc chromosome locus [19]. It is known that the
human chromosome 19 adeno-associated virus integration site 1
(AAVS1) integration site is a “safe harbor site” for the targeted
insertion of foreign genes by producing DNA double-strand breaks
(DSBs) and subsequent repair via homologous recombination (HR)
[20].
In this study, we developed inducible VEGF-secreting hUCB-
MSCs by TALEN-mediated VEGF gene integration into a safe har-
bor site of the chromosome. These engineered stem cells were
capable of secreting VEGF at physiological concentration upon
induction by Dox treatment. VEGF/hUCB-MSCs were implanted in
a MI rat model to assess whether they could enhance angiogene-
sis and provide a cardioprotective effect.
MATERIALS AND METHODS
Isolation and Culture of Human UCB-MSCs
Human UCB-MSCs were isolated as previously described [21, 22].
Human UCB-MSC isolation was performed according to the proce-
dure approved by the Borame Hospital Institutional Review Board
and Seoul National University (IRB No. 0603/001-002-07C1).
Brieﬂy, UCB samples from term and preterm deliveries were har-
vested at the time of birth with the mother’s informed consent
(Seoul City Borame Hospital Cord Blood Bank). The UCB samples
were mixed with the HetaSep solution (StemCell Technologies,
Vancouver, Canada, https://www.stemcell.com) at a ratio of 5:1
and were then incubated at room temperature to deplete eryth-
rocyte counts. The supernatant was carefully collected and mono-
nuclear cells were obtained using Ficoll-Paque PLUS (GE
Healthcare Life Sciences, Marlborough, MA, http://www.gehealth-
care.com) density-gradient centrifugation at 2,500 rpm for 20
minutes. The cells were washed twice in phosphate buffered
saline (PBS) and seeded in growth media consisted of RPMI 1640
medium (11875; Thermo Fisher Scientiﬁc Life Sciences, Waltham,
MA, http://www.thermoﬁsher.com) containing 10% fetal bovine
serum. The medium was changed at 48-hour intervals and the
cells were subcultured after they reached 90% conﬂuence, unless
described.
Designing New TALEN Vectors and Inducible VEGF
Donor Vectors
Supporting Information Figure 1A shows the TALEN domains that
consisted of speciﬁc binding sequences targeting the AAVS1 locus
(safe harbor site) and the FokI nonspeciﬁc endonuclease domains.
The left and right TALEN plasmids were newly constructed as fol-
lows. The target sequences of the chromosome 19 AAVS1-
targeting TALENs were: 50-TGGAGCCATCTCTCTCCTT-30 (Left)—
gccagaacctctaa (spacer)—50-GGTTTGCTTACGATGGA-30 (Right). The
plasmids encoding the TALENs targeting this sequence were pre-
pared as previously described [23]. To prepare the efﬁcient target-
ing donor DNA, we designed several new 800 base pair (bp)
homology arms. The initial targeting vector with the left and right
homology arm (HA-L and HA-R) cassette containing the inducible
VEGF gene did not produce a sufﬁcient number of cells integrated
with the gene cassette. Therefore, we redesigned several TALEN-
L/R targeting vectors along with several HA-Ls and HA-Rs in donor
vectors and tested their efﬁciency. Finally, we could generate an
efﬁcient combination of TALEN-L/R targeting vector and HA-L and
HA-R donor vector cassette for the AAVS1 locus by giving a 50 bp
space apart between the homology arms and the TALEN target
sites. The homology arms were polymerase chain reaction (PCR)-
ampliﬁed from human genomic DNA and cloned into the pGEM T-
Easy vector. The left and right homology arms were isolated using
pairs of restriction enzymes (KpnI/AgeI/NotI for the left and NotI/
EcoRI/SphI for the right homology arms) and cloned into the
KpnI/SphI site of the pUC19 vector.
The inducible donor vectors were constructed using three
DNA fragments. The Tet-on mini-CMV promoter (Addgene, Cam-
bridge, MA, https://www.addgene.org), VEGF cDNA (synthesized
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by Bioneer, Daejeon, Korea, http://www.bioneer.co.kr), and
hEF1a-rtTA-pA (Addgene, Cambridge, MA, https://www.addgene.
org) were ampliﬁed by PCR using speciﬁc primers containing the
ﬂanking sequences. Each ampliﬁed DNA fragment was cloned into
the pZDonor-AAVS1-puromycin DNA vector (Sigma-Aldrich, St.
Louis, MO, https://www.sigmaaldrich.com) digested with the AgeI
and EcoRI restriction enzymes (New England BioLabs, Ipswich,
MA, https://www.neb.com) using the In-Fusion HD Cloning Kit
(TaKaRa Bio, Inc., Kusatsu, Japan, http://www.takara-bio.com) (Fig.
1). Then, the whole insert TetO-CMV-VEGF-hEF1a-rtTA was trans-
ferred intothe pUC19-AAVS1 donor vector that contained newly
designed HA-L and HA-R sequences to target to the chromosome
19 AAVS1 site.
TALEN-Mediated Homologous Recombination
TALEN-mediated AAVS1 site integration of an inducible VEGF-
secreting cassette into a safe harbor site hUCB-MSCs was accom-
plished in two steps (Fig. 1B). First, the TALEN left (L) and right (R)
arms bind to their target sequences in the host chromosome and
the FOKI endonuclease induces a DNA DSB. Then, the DSB is
repaired by the HR machinery using a pUC19-TetO-CMV-VEGF-
hEF1a-rtTA donor vector. Cells (83 105) seeded on a 60-mm dish
were transfected with TALEN left (L), right (R) (1.5 lg) and the
pUC19-TetOn-CMV-VEGF-hEF1a-rtTA donor vector (3 lg). At 5
days post-transfection, the medium was changed; then, the cells
were subcultured two times at 4.5 day intervals. After 2 weeks,
genomic DNA was isolated from the hUCB-MSCs by adding 1 ml
of the SNETextraction buffer per 106 cells (20 mM Tris-HCl [pH 8],
5 mM EDTA [pH 8], 400 mM NaCl, and 1% SDS) containing
100mg/ml proteinase K (Sigma-Aldrich, St. Louis, MO, http://
www.sigmaaldrich.com). The DNA samples were incubated at
558C for 2 hours. Proteinase K was inactivated by incubating the
DNA samples at 988C for 10 minutes; then, RNase (1 mg/ml) was
added and the cells were incubated at 378C for 30 minutes. The
DNA was precipitated and its concentration was determined by
spectrophotometry. TALEN-mediated HR was detected using PCR
genotyping. PCR ampliﬁcation of the genomic DNA was per-
formed using the following parameters: an initial denaturation
step at 948C for 5 minutes, followed by 35 cycles at 948C for 15
seconds, 658C for 45 seconds, and 728C for 150 seconds with a
ﬁnal extension step at 728C for 10 minutes. The ampliﬁed products
were analyzed on a 1% agarose gel. The ampliﬁcation of 2160 bp
and 2007 bp PCR fragments indicated the site-speciﬁc integration
of the inducible VEGF-secreting donor cassette into the AAVS1
locus (Fig. 1C).
Preparation of Secreted Proteins and Western Blotting
Secreted proteins were collected from the VEGF/hUCB-MSCs and
hUCB-MSCs. After culturing the cells in growth medium for 3
days, the cells were washed ﬁve times with serum-free media and
incubated with serum-free media for 24 hours. Proteins in the
conditioned media were precipitated with 10% (vol/vol) trichloro-
acetic acid (Sigma-Aldrich) at 48C. The protein pellets were air
dried prior to use. Western blot analysis was performed as previ-
ously described [24]. Brieﬂy, hUCB-MSCs were washed twice with
cold PBS and lysed with RIPA buffer containing protease inhibitors
(Roche, Basel, Switzerland, http://www.roche.com). For primary
antibody labeling, rabbit anti-ﬂag antibody (1:5000; Santa Cruz
Biotechnology, Santa Cruz, CA, http://www.scbt.com) and rabbit
anti-human VEGF polyclonal antibody (1:2,000, AbClon, Seoul,
Korea, http://abclon.com) were used. An horse radish peroxidase
(HRP)-conjugated anti-rabbit IgG antibody (1:2,000, Enzo Life Sci-
ences, Farmingdale, NY, http://www.enzolifesciences.com) was
used as a secondary antibody.
VEGF165-a Enzyme-Linked Immunosorbent Assay
(ELISA) Measurements
VEGF165-a in the cell culture supernatants was quantiﬁed using a
Quantikine mouse VEGF immunoassay ELISA kit (R&D Systems,
Minneapolis, MN, https://www. rndsystems.com). The cells were
washed twice with PBS, and the media was changed to keratino-
cyte serum-free medium (KSFM) for the hUCB-MSC and VEGF/
hUCB-MSC (Dox2) groups. For the VEGF/hUCB-MSCs (Dox1)
group, 500 ng/ml of Dox was added. After incubation for 1 day,
1 ml of medium in a 60-mm dish was harvested from each group.
The conditioned media was ﬁltered and analyzed by ELISA in
duplicate. The results were normalized for the number of cells in
the dish and the time of exposure to the cells.
Subcutaneous Transplantation of VEGF/hUCB-MSCs on
Cell Sheets
VEGF/hUCB-MSC cell sheets were subcutaneously transplanted
on the mouse dorsal skin as previously described [25]. Brieﬂy,
VEGF/hUCB-MSCs were cultured on the UpCell surface at a den-
sity of 1 3 106 cells per 35-mm dish. Six female mice were anes-
thetized and the dorsal skin was lifted and cut vertically. The cell
sheet was transferred onto a polyvinylidene diﬂuoride (PVDF)
membrane and the PVDF membrane was slowly removed. Doxy-
cycline was added to the drinking water at a concentration of 1
mg/ml. Eight days after transplantation, the animals were sacri-
ﬁced for analysis.
Cell-Matrigel Transplantation into Severe Combined
Immunodeficiency (SCID) Mice
The hUCB-MSC and VEGF/hUCB-MSCs cell suspension was
washed once with PBS to remove all traces of trypsin. After cen-
trifugation at 300g for 5 minutes, the supernatant was decanted
and the cell pellets were resuspended to yield a ﬁnal concentra-
tion of 13 106 cells per 100 ml in Matrigel for transplantation into
mice. The animal protocol was approved by the Seoul National
University Institutional Animal Care and Use Committee (IACUC)
prior to the experiment. Vascular formation was evaluated in 7- to
8-week-old female SCID mice (OrientBio, Seongnam, SouthKorea,
www.orient.co.kr). Matrigel was loaded with a ﬁnal concentration
of 1 3 106 cells per 100 ml. The injection sites were cleaned with
ethanol twice prior to injection of Cell-Matrigel into each site
using 1 ml syringes and 27 G needles. Eight days after the injec-
tions, the animals were sacriﬁced for analysis.
MI Rat Model and Cell Transplantation
The MI rat models were surgically induced as previously described
[5]. Brieﬂy, Male Sprague-Dawley rats weighting 260–300 g (Ori-
entBio, Seongnam, SouthKorea, www.orient.co.kr) were used for
the MI model. All animal procedures were performed in accord-
ance with the guidelines of the SNU IACUC. After MI induction,
the rats were divided into four treatment groups: rats that
received VEGF/hUCB-MSCs (n5 12, later divided into two
groups), hUCB-MSCs (n5 6), or a sham operation (Control, n5 6).
Immediately after the MI induction surgery, the UpCell sheets
layered with VEGF/hUCB-MSC or hUCB-MSC cells on PIPAAm-
grafted surfaces were detached from the plates by incubating at
208C for 20 minutes. Then, the cell sheets were attached to
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Figure 1. Generation of VEGF/hUCB-MSCs and conﬁrmation of conditional VEGF secretion. (A): Schematic illustration of producing inducible
VEGF-secreting hUCB-MSC cells and cell sheet transplantation in the rat myocardial infarction model. The human UCB-MSCs secreting VEGF
were seeded onto a cell sheet for transplantation to the myocardial infarction site of rat hearts. (B): The integration of the inducible VEGF
secretion DNA cassette into the AAVS1 site following the TALEN-mediated DNA double-strand break. HR (L) and HR (R), the left and right
arms for homologous recombination. FP and RP, forward primer and reverse primer binding sites for the PCR primers. (C): Junction PCR analy-
sis for the conﬁrmation of the integrated inducible VEGF secretion cassette with two different PCR primer sets. For validation of the gene
integration into the UCB-MSC genome, two sets of primers were used to detect the speciﬁc sites; a 2.16 kb fragment with the AAVS1 (for-
ward) and VEGF (reverse) region primers and a 2007 base pair (bp) fragment with thehEF1a (forward) and AAVS1 (reverse) region primers.
(D): Western blotting analysis detected inducible VEGF expression in VEGF/hUCB-MSC cell lysates and (E) inducible VEGF secretion in the
VEGF/hUCB-MSC culture media. The Dox treatment was maintained for 48 hours. (F): Quantiﬁcation of the secreted VEGF in the VEGF/hUCB-
MSC (Dox1) culture media 2 days after transient transfection and (G) 2 weeks after stable transduction. The amount of VEGF production is
indicated as ng per 23 106 cells per day on the Y-axis. The error bars indicate the SEM of three replicate measurements per group. (*p< .05,
**p< .01). Abbreviations: AAVS1, adeno-associated virus integration site 1; Dox, doxycycline; hUCB-MSCs, human umbilical cord blood-
derived mesenchymal stem cells; HA-L, left homology arm; HA-R, right homology arm; HR, homologous recombination; TALEN, transcription
activator-like effector nuclease; VEGF, vascular endothelial growth factor.
J_ID: SCTM Customer A_ID: SCTM12003 Cadmus Art: SCTM12003 Ed. Ref. No.: SCTM-16-0114.R1 Date: 23-February-17 Stage: Page: 1043
ID: srinivasanv Time: 18:31 I Path: //chenas03/Cenpro/ApplicationFiles/Journals/Wiley/SCTM/Vol00603/160001/Comp/APPFile/JW-SCTM160001
Cho, Kim, Chang et al. 1043
www.StemCellsTM.com Oc 2017 The Authors
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
polypropylene supporting membranes (Thermo Fisher Scientiﬁc
Life Sciences, Waltham, MA, http://www.thermoﬁsher.com) and
transplanted onto the injured epicardial anterolateral area. Seven
minutes after transplantation, the supporting membrane was
removed and the cell sheets showed stable attachment. The same
procedures were repeated to make a bilayer cell sheet composed
of 2 3 106 hUCB-MSCs and VEGF/hUCB-MSCs cells. To prevent
the rat’s immune rejection of the human cells, all rats received
cyclosporine as previously described [5].
Functional Assessment of the Infarcted Myocardium
The cardiac functional assessment was performed as previously
reported by our group [5]. Brieﬂy, cardiac functions were assessed
by transthoracic echocardiography prior to MI surgery (normal
base line) and 1 week and 3 weeks after MI for each cell trans-
plantation group.
Histological and Immunohistochemical Examinations
Histological and Immunohistochemical examinations were per-
formed as previously reported by our group [5]. Brieﬂy, Hearts
were harvested and ﬁxed in 4% paraformaldehyde for 24 hours
and then cut into four transverse slices through the infarcted area.
The slices were embedded in parafﬁn, and 5 lm histologic sec-
tions were stained with Masson’s Trichrome.The infarct size, ﬁbro-
sis, and scar thickness were quantiﬁed using the ImageJ software
(NIH, Bethesda, MD, USA).
Statistical Analysis
All statistical analyses were performed with SPSS version 20.0
(IBM, Armonk, NY, http://www.ibm.com). A Kruskal-Wallis test
was used to assess differences among the groups. The Mann-
Whitney U test was performed as the post hoc test. A p value less
than .05 was considered to be statistically signiﬁcant.
RESULTS
Genetic Engineering of an Inducible VEGF-Expressing
DNA Cassette Into the hUCB-MSC Chromosome by
TALEN-Mediated Genome Editing
Figure 1A illustrates production of inducible VEGF-secreting hUCB-
MSC cells and cell sheet transplantation in the rat MI model. To
conﬁrm whether the inducible VEGF expression system from the
VEGF/hUCB-MSCs is properly induced by treatment with Dox,
western blotting was performed on VEGF/hUCB-MSC samples.
VEGF expression and secretion were detected in the cell lysates
(Fig. 1D) and secreted media (Fig. 1E) after Dox treatment for 48
hours. In the transient episomal plasmid transfection experiment,
we observed the induction of the VEGF secretion into the media
after Dox treatment by ELISA (Fig. 1F). Similar VEGF levels were
measured in the VEGF/hUCB-MSC cells with the inducible system
integrated into the chromosome by TALEN-mediated genome
editing (Fig. 1G). Too high a continuous level of VEGF is known to
result in angioma formation, which is one of the main obstacles
for VEGF therapy. Thus, the VEGF concentration is the main con-
sideration for the treatment of ischemic disease with VEGF. In our
study, the VEGF concentration secreted into the media following
induction was 50.74 ng/106 cells per day, which was within the
physiological concentration range (32.3–70 ng/106 cells per day).
It is known that the VEGF expression by viral infection continu-
ously secreted VEGF but resulted in large variations (100–191.2
ng/106 cells per day) and the concentration could easily cause the
hemangiomas [14]. From our results, we conﬁrmed that VEGF/
hUCB-MSCs harboring an inducible VEGF gene in a safe harbor
site secreted VEGF into the cell culture media in the physiological
therapeutic concentration range.
Increased Angiogenic Markers and Decreased Cell Cycle
Inhibitor Expression by VEGF Induction
To examine the biological effects of VEGF secreted from VEGF/
hUCB-MSCs, we compared the expression levels of angiogenic
markers and cell cycle-related genes in each group by real-time
RT-PCR. At 48 hours after the induction of VEGF secretion by Dox,
the VEGF/hUCB-MSCs showed a signiﬁcant increase in the expres-
sion of the angiogenic markers FLK1, NRP1, and ANGPT1, and a
reduction in the expression of the cell cycle arrest- and
senescence-related genes p21 and p16 (Fig. 2). These results indi-
cate that the VEGF/hUCB-MSCs exhibit EC-like marker characteris-
tics through VEGF autocrine effects.
Functional Assessment of Transplanted VEGF/hUCB-
MSCs in a Mouse Model
Prior to the application of VEGF/hUCB-MSCs to the MI animal
model, we ﬁrst tested: (a) whether VEGF was secreted properly by
the VEGF/hUCB-MSCs upon Dox treatment in vivo and (b)
whether VEGF secreted from VEGF/hUCB-MSCs could enhance
neoangiogenesis.
To conﬁrm VEGF secretion by the implanted VEGF/hUCB-
MSCs, we divided the mice into three groups: the hUCB-MSC cell
only group, the VEGF/hUCB-MSC without Dox group and the
VEGF/hUCB-MSC with Dox group. Using an UpCell transplantation
system, hUCB-MSC or VEGF/hUCB-MSC cell sheets were trans-
planted onto the skin on the backs of the mice. For the VEGF/
hUCB-MSC (Dox1) group, the mice were freely administered Dox
in their drinking water (1 lg/ml) for 4 days starting one day after
UpCell transplantation of VEGF/hUCB-MSCs (Fig. 3A). VEGF
expression was detected in the transplanted subcutaneous tissues
in the Dox (1) group mice by Western blot analysis using anti-Flag
and anti-VEGF antibodies (Fig. 3B). The amount of secreted VEGF
from the extracted subcutaneous tissue was quantiﬁed by ELISA.
Signiﬁcantly higher levels of VEGF were detected in the VEGF/
hUCB-MSC (Dox1) group mice (15.4 ng/mg) compared to the
Dox2 and cell only groups (Fig. 3C).
To test the angiogenetic function of the VEGF/hUCB-MSCs, we
subcutaneously injected the mice with Matrigel mixed with VEGF/
hUCB-MSCs (Fig. 3D). The injected Matrigel plugs were removed 8
days after implantation. The plugs of the Dox-fed mice showed a
more reddish color compared with the group not provided Dox,
indicating greatly enhanced angiogenesis (Fig. 3E). Immunostain-
ing of the Matrigel with an anti-VEGF antibody (Fig. 3F) and an
anti-von Willibrand factor (vWF) antibody (Fig. 3G) showed high
levels of VEGF secretion and higher levels of blood vessel forma-
tion in the doxycycline-treated group. These results demonstrated
that the inducible VEGF-secreting hUCB-MSC cells secreted VEGF
within normal physiological ranges and induced neo-
vascularization in vivo following doxycycline treatment.
Enhanced Cardiac Function by VEGF Secretion from
VEGF/hUCB-MSCs in the Rat MI Model
Next, we tested whether the VEGF/hUCB-MSCs could enhance
cardiac function upon VEGF induction in the rat MI model.
Twenty-four rats received MI surgery and the rats were divided
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into four group; Control, hUCB-MSCs or VEGF/hUCB-MSCs
(Dox2), VEGF/hUCB-MSCs (Dox1). After conﬁrming the infarct by
visual inspection, the cell sheets were transplanted into the
infarcted region 30 minutes after MI induction. Echocardiography
was performed to evaluate the therapeutic efﬁcacy of VEGF secre-
tion in combination with VEGF/hUCB-MSC cells in the rat MI-
induced heart. To monitor the consistency of the infarction proce-
dure and size, we compared left ventricular ejection fraction
(LVEF) and left ventricular fractional shortening (LVFS) values of
Pre-MI (baseline) and Post-MI using echocardiography and con-
ﬁrmed the consistency of infracted heart surgery (Supporting
Information Fig. 2). Then, healthy heart function indicators (i.e.,
ejection fraction [EF], fractional shortening [FS], left ventricle inner
diameter at diastole [LVIDd], and left ventricle inner diameter at
systole [LVIDs]) were measured 1 week and 3 weeks after the cor-
onary artery ligation and implantation (Fig. 4A, 4B). One week
after transplantation of VEGF/hUCB-MSCs (Dox1), the values of
LVIDd, LVIDs, EF, and FS showed improved heart function com-
pared with the hUCB-MSC alone and VEGF/hUCB-MSC (Dox2)
groups. Further improved cardiac functions were observed 3
weeks after the treatment. Left ventricle (LV) dilation and dysfunc-
tion was reduced in the VEGF/hUCB-MSC (Dox1) group compared
to the control and other groups (Fig. 4C). Three weeks after implan-
tation, the EF in the VEGF/hUCB-MSC (Dox1) group (65.3963.5%)
was much higher than the EF in the control (35.3164.10%),
hUCB-MSC (49.9564.19%), and VEGF/hUCB-MSC (Dox2)
(49.2462.92%) groups (Fig. 4D). Similarly, fraction shortening in
the VEGF/hUCB-MSC (Dox1) group (31.8761.94%) was signiﬁ-
cantly higher compared to the control (14.6161.88%), hUCB-MSC
(2261.87%), and VEGF/hUCB-MSC (Dox2) (21.8062.28%)
groups (Fig. 4E). Although the LVIDd values in the hUCB-MSC alone
(8.7160.32 mm) and VEGF/hUCB-MSC (Dox2) (8.4360.87 mm)
groups were slightly reduced compared to the control group
(9.8360.61 mm), the VEGF/hUCB-MSC (Dox1) group (6.426
0.26 mm) showed a signiﬁcant reduction (p< .01).
Reduced MI Size and Fibrosis but Thicker Left Ventricle
Due to VEGF Secretion by VEGF/hUCB-MSCs in the Rat
MI Model
We conducted histological and histomorphometric analyses to
better understand the improvement of cardiac function by Mas-
son’s trichrome staining of the rat hearts at 3 weeks after implan-
tation. Fibrosis due to MI appears blue and the preserved
myocardium appears red in Masson’s trichrome staining. Dramatic
LV wall thinning was detected in the MI model in the hUCB-MSC
alone group. The VEGF/hUCB-MSC(Dox2) group showed a minor
protective effect. However, an improved anti-ﬁbrosis effect was
observed in the LV wall in the rats treated with VEGF/hUCB-MSCs
(Dox1) (Fig. 5A, Supporting Information Fig. 3). The MI size was
greatly reduced in the VEGF/hUCB-MSC (Dox1) group compared
to the MI control, hUCB-MSC alone, and VEGF/hUCB-MSC (Dox2)
groups (Fig. 5B). The ventricular ﬁbrosis rate was signiﬁcantly
reduced in the VEGF/hUCB-MSC (Dox1)-treated rats compared
with the other groups (Fig. 5B). However, the LV wall thickness of
the VEGF/hUCB-MSC (Dox1) group was signiﬁcantly thicker than
the MI, hUCB-MSC alone, and VEGF/hUCB-MSC (Dox2) groups
(Fig. 5B).
Immunohistochemical staining was performed to investigate
Dox-induced VEGF secretion in the infarcted area following treat-
ment with VEGF/hUCB-MSC1Dox. Heart tissues were stained
with a VEGF antibody. The infarcted area in the VEGF/hUCB-MSC
(Dox1) group showed high expression of VEGF, which was not
observed in the control, hUCB-MSC, and VEGF/hUCB-MSC (Dox2)
groups (Fig. 6A). These results suggested that VEGF was secreted
properly by the VEGF/hUCB-MSC cells upon doxycycline treat-
ment. Furthermore, anti-vWF staining showed that the VEGF/
hUCB-MSC (Dox1) group had signiﬁcantly increased vessel den-
sity in the infarcted area, whereas the hUCB-MSC alone and
VEGF/hUCB-MSC (Dox2) groups showed small increases in vessel
density compared to the control group (Fig. 6B). These results sug-
gest that VEGF secreted from VEGF/hUCB-MSCs greatly enhanced
neoangiogenesis compared to stem cell therapy alone by directly
and indirectly stimulating angiogenic factors or EC cell-like factors.
Prolonged Cell Survival of Transplanted Human
VEGF/hUCB-MSCs in the Infarcted Region
To determine the effects of VEGF secreted from VEGF/hUCB-MSCs
(Dox1) on the survival of transplanted human stem cells, we
Figure 2. Effect of VEGF secretion from VEGF/hUCB-MSCs on the
gene expression of neoangiogenesis markers and cell cycle regula-
tors. (A–C): Induced VEGF enhanced the expression of angiogenesis-
related markers. The mRNA levels of Flk-1, NRP1, and ANGPT1 in
VEGF/hUCB-MSCs (Dox1) were evaluated by comparing to control
hUCB-MSCs (Con) and VEGF/hUCB-MSCs (Dox2) using real-time RT-
PCR. (D, E): Cell cycle regulation in VEGF/hUCB-MSCs in response to
secreted VEGF. Secreted VEGF from VEGF/hUCB-MSCs (Dox1)
decreased cell cycle inhibitors (p21 and p16), suggesting that VEGF
had a positive effect on hUCB-MSC survival. The experiments were
performed in triplicates, and the data were presented as the
means6 SE. (*p< .05, **p< .01, n5 3). Abbreviations: Dox, doxycy-
cline; hUCB-MSCs, human umbilical cord blood-derived mesenchymal
stem cells; clease; SE, standard error; VEGF, vascular endothelial
growth factor.
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Figure 3. The induction of VEGF expression by VEGF/hUCB-MSCs transplanted on mouse skin and neoangiogenesis by secreted VEGF in Matri-
gel plugs. (A): In vivo test design for the transplantation of the UpCell seeded with hUCB-MSCs secreting VEGF. (B, C): Western blot and ELISA
analysis for VEGF secreted at the UpCell transplantation site. Error bars indicate the SEM of three replicate measurements per clone or popula-
tion. (**p< .01, n5 3). (D): Design of the blood vessel induction test in Matrigels with VEGF/hUCB-MSCs. (E): Blood vessels formed in the
Matrigel containing VEGF/hUCB-MSCs without doxycycline (Dox2) and with doxycycline (Dox1). (F, G): Immunohistochemical staining for VEGF
and newly formed vessels by vWF in Matrigel with VEGF/hUCB-MSCs (Dox2 or Dox1). (Scale bar: 100 lm). Abbreviations: Dox, doxycycline;
hUCB-MSCs, human umbilical cord blood-derived mesenchymal stem cells; VEGF, vascular endothelial growth factor; vWF, von Willibrand factor.
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Figure 4. Engraftment of VEGF/hUCB-MSCs and recovery of cardiac function. (A): Schematic illustration of treatment of MI by VEGF/hUCB-
MSCs. Echocardiography measurements performed 1 week and 3 weeks after MI induction and cell transplantation. (B): The image of an MI
and the transplantation process of the UpCell system. (C): Representative echocardiogram images in the MI site after 3 weeks. The infarcted
rat heart served as the control for transplantation with hUCB-MSCs, VEGF/hCUB-MSC (Dox2), and VEGF/hUCB-MSC (Dox1). In the quantita-
tive analysis, treatment of VEGF/hUCB-MSCs with doxycycline signiﬁcantly enhanced the cardiac function in 1 week and 3 weeks. The VEGF/
hUCB-MSC (Dox1) group showed (D) an increase in the EF and (E) FS and (F) a decrease in the LVIDd and (G) LVIDs. (*p< .05, **p< .01,
n5 6 each group). All values represent the mean6 SE. Abbreviations: Dox, doxycycline; EF, ejection fraction; FS, fractional shortening; hUCB-
MSCs, human umbilical cord blood-derived mesenchymal stem cells; LVIDd, left ventricle inner diameter at diastole; LVIDs, left ventricle inner
diameter at systole; MI, myocardial infarction; SE, standard error; VEGF, vascular endothelial growth factor.
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detected transplanted VEGF/hUCB-MSC in rat hearts via immuno-
histochemical staining. An anti-lamin A1C antibody was used to
detect human cells in the infarcted region. Lamin A1C-positive
cells were not detected in the MI control group (Fig. 6).
Signiﬁcant numbers of transplanted human cells were detected
above the myocardium of the hUCB-MSC alone and VEGF/hUCB-
MSC(Dox2)-transplanted groups. However, in the VEGF/hUCB-
MSC (Dox1) group, a large number of Lamin A1C-positive cells
were detected above the myocardium (Fig. 6). These results indi-
cate that secreted VEGF also has a positive effect on stem cell sur-
vival and thus leads to the induction of enhanced paracrine
effects and improved protection from cardiac damage.
DISCUSSION
Stem cell-based therapy has been widely investigated for the
treatment of MI. In recent studies, stem cell therapy using MSCs
offered a positive result for the treatment of MI due to paracrine
effects and revascularization [26]. However, the application of cell
therapy faces many obstacles due to the low survival of the
implanted cells and insufﬁcient oxygen and nutrients. Moreover,
cardiomyocytes have a limited regeneration capacity [27]. To over-
come these obstacles with ischemic disease, combined therapy
using vascular stimulating growth factor and MSCs is required. In
our previous study, VEGF protein delivery with stem cells showed
a therapeutic effect on ischemic disease [28]. However, the pro-
tein therapy highlighted the limitation of the application periods
due to the short half-life of the VEGF proteins [29]. To overcome
this limitation, several studies reported genetic modiﬁcations
using retroviruses for the integration of transgenes into the host
chromosome to induce their long-term expression [30, 31]. How-
ever, retroviruses can produce oncogene activation or tumorigen-
esis due to the random and unpredictable integration of the
transgene, which is a major side effect. Furthermore, uncontrolled
VEGF expression also causes side effects such as hemangioma and
nonstandard blood vessel formation. To address these issues, we
generated an inducible VEGF-secreting stem cell using TALEN-
mediated transgene integration into a speciﬁc safe harbor site by
AAVS1 locus-directed HR. With this TALEN-mediated safe harbor
gene delivery strategy, the hUCB-MSCs were able to secrete VEGF
upon doxycycline treatment, protect the host from cardiac dam-
age and improve cardiac function in a rat MI model.
There have been a number of studies utilizing the UCB-MSCs
to treat the infracted heart. Various strategies such as biomateri-
als, growth factors, and tissue engineering have been applied and
many progress were shown, but therapeutic limits existed in these
studies [5–7]. However, UCB-MSCs were reported promising cell
sources for cardiac repair and good candidate for vascular growth
[6]. To increase the therapeutic potential of UCB-MSCs, it requires
stimulation by growth factors such as VEGF. In our results, the
VEGF signal was easily adjustable. Furthermore, various materials
have been applied to enhance the implanted cell survival, and
these materials enhance the effectiveness of hUCB-cell therapy.
However, these materials remained the retention and low cell sur-
vival problems. In this study, we used a cell patch that delivers
cells only because the cell sheets are removed after cell implanta-
tion. The needle injection of stem cells into infarcted myocardium
was some routine procedures in the preclinical studies. However,
the needle injection has some unsafe concerns for implantation of
stem cells on the cardiac tissue. It shows the low transplant rates
and difﬁculty for treating the large areas [32], and the needle may
induce the mechanical injury and myocardial damages [33, 34].
Conversely, the positive effect of the cell sheet has been validated
previously [35]. It easily grafted and the transplantation method is
Figure 5. Evaluation of MI size, left ventricle (LV) ﬁbrosis and wall
thickness after the transplantation of VEGF/hUCB-MSCs. (A): Repre-
sentative images of heart sections stained with Masson’s trichrome
show ﬁbrosis and wall thinning at the infarcted area. Fibrotic areas
are colored in blue and the viable myocardium is colored in red. (B):
Infarct size, percentage of LV ﬁbrosis, and LV wall thickness were
compared among the different groups. (*p< .05, **p< .01). All val-
ues represent the mean6 SE. (Scale bar5 5 mm). Abbreviations:
Dox, doxycycline; hUCB-MSCs, human umbilical cord blood-derived
mesenchymal stem cells; MI, myocardial infarction; SE, standard
error; VEGF, vascular endothelial growth factor.
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safe and a high rate of successful transplantation was accom-
plished in our study.
TALENs have been successfully applied to edit targeted
genomes in various cell types [19, 36]. However, the limitations
associated with engineered nucleases remain. The expression
of TALEN pairs could cause additional DNA cleavage in human
cells, and this unexpected DNA cleavage at off-target sites
could reduce cell survival and cell cycle arrest [18]. To predict
off-target cleavage activities, high-throughput sequencing
assessment is required. In previous reports, the off-target cleav-
age activities of AAVS1-speciﬁc TALENs were investigated and
revealed to be approximately 0.13% [20, 37]. Although we did not
proﬁle TALEN off-target activity using whole genome sequencing in
a VEGF/hUCB-MSC cell population in this study, similar activities
were expected. When we tested the three sites with the highest
homology to AAVS1 safe harbor site by PCR, the results showed no
off-target integration.
The apparent improvement observed for this combination
therapy can be explained as follows. First, the impaired cardiac tis-
sue may have been regenerated better by the transplanted stem
cells. According to our previous results and this result, trans-
planted MSCs could regenerate the impaired cardiac tissue and
promote the proliferation of cardiac progenitor cells near the
transplanted area [5]. This is supported by our results that higher
vWF staining is observed in the VEGF/hUCB-MSCs (Dox1) group
and also human MSC cells are remained in the implanted site as
demonstrated by human Lamin A1C staining. However, it was
hard to show that the human MSCs actually formed vascular EC
or not. However, the cardiac regenerative effect was not clearly
observed in our MSC alone group, and other researchers also
reported that the frequency of the occurrence of these regenera-
tive processes by MSC was also very low [38]. However, our com-
binatorial approaches of induced VEGF and VEGF/hUCB-MSCs
greatly contributed to the prevention of LV remodeling and the
protection of the remaining cardiomyocytes as well as cardiac
regeneration. Thus, as previously reported by others and our stud-
ies, the major therapeutic effect might come from VEGF paracrine
effect of the engineered VEGF/hUCB-MSCs (Dox1) cells in addi-
tion to the MSC paracrine effect itself. The second explanation for
these positive results is the paracrine effects of the combination
therapy. Previous studies also suggested that the main therapeutic
effect of transplanted MSCs occurred due to paracrine effects [4,
39]. The transplanted cells secrete many cytokines, and these
cytokines activate cell survival, alleviate the ﬁbrosis, and
Figure 6. Immunohistochemical staining of VEGF, blood vessel formation by VEGF/hUCB-MSCs and implanted human cell engraftment. Myocar-
dial infarction (MI)-induced rats were divided into four groups. Control (MI alone), treated with hUCB-MSCs, VEGF/hUCB-MSCs (Dox2), and VEGF/
hUCB-MSCs (Dox1). (A): VEGF staining was performed at the infarcted area. High levels of VEGF were detected only in the VEGF/HUCB-MSC
(Dox1) group. (B): Generation of blood vessels in the MI regions. More blood vessels were observed in VEGF/hUCB-MSC (Dox1) group than other
groups. (C): An anti-human Lamin A1C antibody was used to visualize the transplanted human stem cells. More human Lamin A1C positive cells
were observed in rat hearts transplanted with VEGF/hUCB-MSC (Dox1). (Scale bar5 100 lm). Abbreviations: AAVS1, adeno-associated virus inte-
gration site 1; Dox, doxycycline; hUCB-MSCs, human umbilical cord blood-derived mesenchymal stem cells; VEGF, vascular endothelial growth fac-
tor; vWF, von Willibrand factor.
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contribute to cardiomyocyte preservation. Furthermore, tuning
the cytokine secretion toward angiogenic factors will further help
the therapeutic effect of stem cells in MI. Indeed, our data
showed that the induced VEGF could enhance the release of cyto-
kines related to the angiogenic paracrine such as cytokine Angio-
poietin 1 (Fig. 2), and ﬁnally prevent cardiac remodeling by
improving implanted cell survival in the harshly infarcted region.
These VEGF stimulating paracrine effects were also demonstrated
in myoblast and EC in mouse model [40, 41]. Third, VEGF/hUCB-
MSCs and secreted VEGF promoted neovascularization in the
implanted area and this neovascularization might maintain VEGF/
hUCB-MSC survival after cell sheet integration and the cells’ thera-
peutic functions in the MI microenvironment. Our data showed
that more neovascularization occurred in the infarcted area when
the engineered cells were boosted with secreted VEGF (Fig. 6).
Other studies also reported that the therapeutic concentration of
VEGF was able to induce stable capillary formation and protect
the remaining cardiomyocytes in MI model [30, 41]. Therefore,
the newly formed vessels also increased the cell survival of the
implanted hUCB/MSCs, thereby contributing to the formation of a
compact cell sheet in the myocardial surface of the infarcted area
as demonstrated by anti-human Lamin A1C staining (Fig. 6). Fur-
thermore, the increased vessel formation may contribute to pro-
tection against negative LV remodeling, the deterioration of heart
tissues and myocardial functional enhancement through an
improved nutrient and oxygen supply.
CONCLUSION
We developed VEGF/hUCB mesenchymal stem cells that could
regulate VEGF secretion. We used TALENs, which offered safe and
high genome editing efﬁciency, to insert the inducible VEGF gene
cassettes into the AAVS1 safe harbor site. In our study, the
secreted VEGF induced neoangiogenesis and increased cell sur-
vival. Furthermore, the combined therapy of mesenchymal stem
cells and controllable VEGF secretion from the cells signiﬁcantly
enhanced angiogenesis, reversed the MI remodeling process and
improved cardiac function. Therefore, inducible VEGF-secreting
safe-harbored VEGF/hUCB-MSC transplantation provides an effec-
tive therapeutic modality for MI.
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